Pablo Ramos-García1, Miguel Ángel González-Moles1,2, Ángela Ayén3, Lucía González-Ruiz4, Isabel Ruiz-Ávila2,5, José Antonio Gil-Montoya1,2. 1. School of Dentistry, University of Granada, Granada, Spain. 2. Instituto de Investigación Biosanitaria, Granada, Spain. 3. School of Medicine, University of Granada, Granada, Spain. 4. Servicio de Dermatología, Hospital General Universitario de Ciudad Real, Ciudad Real, Spain. 5. Servicio de Anatomía Patológica, Complejo Hospitalario Universitario de Granada, Granada, Spain.
Abstract
BACKGROUND: To evaluate the prognostic significance of CTTN/cortactin alterations in head and neck squamous cell carcinoma (HNSCC). MATERIAL AND METHODS: We searched PubMed, Embase, Web of Science, and Scopus for studies published before May 2018. We conducted a meta-analysis to quantify the impact of CTTN/cortactin alterations on clinicopathological and survival variables. RESULTS: Eighteen studies (1633 patients) met inclusion criteria. Quantitative evaluation revealed a strong association of CTTN/cortactin alterations with N+ status (P < .001), higher T status (P < .001), advanced clinical stage (P < .001), high histological grade (P = .001), and lower overall survival (OS) (P < .001). We found heterogeneity in T status, histological grade, and OS and observed small-study effects on N status and OS. In subgroup analyses, a significant association of CTTN amplification and cortactin overexpression with the above variables was preserved. The strongest association between CTTN/cortactin alterations and a worse outcome was observed in the subgroups of Asian patients and pharyngolaryngeal squamous cell carcinomas. CONCLUSIONS: CTTN/cortactin alterations should be evaluated to predict the HNSCC prognosis.
BACKGROUND: To evaluate the prognostic significance of CTTN/cortactin alterations in head and neck squamous cell carcinoma (HNSCC). MATERIAL AND METHODS: We searched PubMed, Embase, Web of Science, and Scopus for studies published before May 2018. We conducted a meta-analysis to quantify the impact of CTTN/cortactin alterations on clinicopathological and survival variables. RESULTS: Eighteen studies (1633 patients) met inclusion criteria. Quantitative evaluation revealed a strong association of CTTN/cortactin alterations with N+ status (P < .001), higher T status (P < .001), advanced clinical stage (P < .001), high histological grade (P = .001), and lower overall survival (OS) (P < .001). We found heterogeneity in T status, histological grade, and OS and observed small-study effects on N status and OS. In subgroup analyses, a significant association of CTTN amplification and cortactin overexpression with the above variables was preserved. The strongest association between CTTN/cortactin alterations and a worse outcome was observed in the subgroups of Asian patients and pharyngolaryngeal squamous cell carcinomas. CONCLUSIONS:CTTN/cortactin alterations should be evaluated to predict the HNSCC prognosis.
Authors: Koos Boeve; Mirjam F Mastik; Lorian Slagter-Menkema; Boukje A C van Dijk; Jan L N Roodenburg; Bernard F A M van der Laan; Max J H Witjes; Bert van der Vegt; Ed Schuuring Journal: Head Neck Date: 2021-05-19 Impact factor: 3.147